home / stock / kzr / kzr news

KZR News and Press, Kezar Life Sciences Inc. From 09/24/23

Stock Information
Company Name: Kezar Life Sciences Inc.
Stock Symbol: KZR
Market: NASDAQ
Website: kezarlifesciences.com
Menu
KZR KZR Quote KZR Short KZR News KZR Articles KZR Message Board
Get KZR Alerts

News, Short Squeeze, Breakout and More Instantly...
KZR - Week In Review: Everest Acquires Novel Autoimmune Therapy In $132 Million Agreement

2023-09-24 22:33:00 ET Summary Shanghai Everest Medicines acquired China/Asian rights to a novel therapy for autoimmune diseases from Kezar Life Sciences of South San Francisco in a deal worth $132.5 million. Once again, a big pharma has returned partnership rights for BeiGene...
KZR - Kezar Life Sciences and Everest Medicines Enter into an Agreement to Develop and Commercialize Zetomipzomib for Lupus Nephritis and other Potential Indications in Greater China, South Korea and Southeast Asia

Partnership with Everest Medicines will address a critical unmet medical need for patients with active lupus nephritis in Asia Kezar is eligible to receive up to $132.5 million in total payments, as well as tiered royalties Kezar Life Sciences, Inc . (Nasdaq: KZR), a clinica...

KZR - CLGN, NAOV, and GRI among top healthcare movers

2023-08-24 10:00:34 ET Gainers: CollPlant Biotechnologies ( CLGN ) +11% NeuBase Therapeutics ( NBSE ) +7% NeuroPace ( NPCE ) +7% Bionomics ( BNOX ) +6% Enhabit ( EHAB ) +16% Losers: NanoVibronix ( NAOV ) -15% ...

KZR - Eton, Semler top healthcare gainers; Cano, Kezar among losers

2023-08-11 10:14:56 ET Gainers: Eton Pharmaceuticals ( ETON ) +23% . Semler Scientific ( SMLR ) +20% . ModivCare ( MODV ) +15% . Erasca ( ERAS ) +9% . Relmada Therapeutics ( RLMD ) +8% . Losers: Cano Health ( CANO ) -...
KZR - Kezar Life Sciences GAAP EPS of -$0.34 in-line

2023-08-11 04:07:07 ET Kezar Life Sciences press release ( NASDAQ: KZR ): Q2 GAAP EPS of -$0.34 in-line. Cash, cash equivalents and marketable securities totaled $236.6 million as of June 30, 2023, compared to $276.6 million as of December 31, 2022. For further detai...

KZR - Kezar Life Sciences Reports Second Quarter 2023 Financial Results and Provides Business Update

PALIZADE global Phase 2b clinical trial evaluating zetomipzomib in lupus nephritis and PORTOLA Phase 2a clinical trial evaluating zetomipzomib in autoimmune hepatitis are both open for enrollment KZR-261 dose escalation study continues to progress and display a favorable safety and tolera...

KZR - RGEN, BGCP and TLS are among after hour movers

2023-06-16 17:39:00 ET Gainers: Kezar Life Sciences ( NASDAQ: KZR ) +6% . Telos Corporation ( TLS ) +4% . Dyne Therapeutics ( DYN ) +4% . Recursion Pharmaceuticals ( RXRX ) +4% . Berry Corporation ( BRY ) +4% . Losers: ...
KZR - IDEX, APRN and CAMP among mid-day movers

2023-06-08 12:49:18 ET Gainers: Airspan Networks Holdings ( MIMO ) +104% . Baosheng Media Group ( BAOS ) +73% . Carvana CVNA +41% . Ideanomics ( IDEX ) +23% . ThermoGenesis Holdings ( THMO ) +23% . Rigetti Computing ( RGTI ) ...

KZR - CP, SBGI and ACOR are among after hour movers

2023-06-07 17:31:50 ET Gainers: 4D Molecular Therapeutics( FDMT ) +21% . Semtech Corporation ( SMTC ) +15% . Acorda Therapeutics ( ACOR ) +10% . scPharmaceuticals  ( SCPH ) +7% . Kezar Life Sciences ( KZR ) +6% . Loser...

KZR - RARE, XP and KZR are among after hours movers

2023-06-05 17:18:34 ET Gainers: GitLab  ( GTLB ) +19% . HealthEquity ( HQY ) +6% . Kezar Life Sciences ( KZR ) +5% . Ultragenyx Pharmaceutical  ( RARE ) +4% . Vaxxinity ( VAXX ) +3% . Losers: Chijet Motor Compan...
Previous 10 Next 10